Nuo Therapeutics, Inc. has filed its quarterly report for the third quarter of 2026, providing insights into its financial performance and operational updates. This filing is crucial as it sheds light on the company's current standing and future prospects within the surgical and medical instruments and apparatus industry.
Company Overview
Nuo Therapeutics, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company trades under the ticker symbol AURX on the OTC exchange. As a smaller reporting company, Nuo Therapeutics is categorized as a non-accelerated filer, indicating its ongoing commitment to transparency and regulatory compliance.
What the Filing Says
The latest filing, dated November 13, 2026, covers the period ending September 30, 2026. Specific details regarding financial metrics and operational highlights were not disclosed in the filing. However, the report is expected to include critical data such as revenue, expenses, and any significant developments impacting the company’s operations.
Impact
This quarterly report is likely to affect various stakeholders, including investors, analysts, and industry competitors. As Nuo Therapeutics continues to navigate its financial landscape, the insights gained from this filing may influence investor sentiment and strategic decisions within the surgical and medical instruments sector.
What's Next
Details regarding future actions or subsequent filings were not specified in the report. Stakeholders will need to await further updates from the company to understand its next steps and potential impacts on its business strategy.
Source: SEC Accession Number 0001437749-26-036956
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










